Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Change in Receivables for 2 consecutive years, with -$11.2 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 251.0% to -$11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.2 million through Dec 2025, up 110.46% year-over-year, with the annual reading at $17.2 million for FY2025, 110.46% up from the prior year.
  • Change in Receivables hit -$11.2 million in Q4 2025 for ARS Pharmaceuticals, down from $14.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $14.0 million in Q3 2025 to a low of -$11.2 million in Q4 2025.